Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Alaunos Therapeutics, Inc.TCRT · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required |
| Reliability | 0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| Peer failure rate | 0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | under $12.5M assetstotal assets $3.0M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | short runway, thin data, degenerate inputsnot computable: dilution, distress, fortress balance sheet |
| Inputs computable | 5 of 14 |
| Graded from | filings received through Apr 30, 2026162 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $0.792026-10-08; market equity $2.0M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 31, 2026; the document on sec.gov.
We are a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. On March 2, 2026, we announced positive preclinical proof-of-concept data for ALN1003 from two separate studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice maintained on a high-fat diet (60% of calories from fat).
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 8.9 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (45.7%) | [1,4-6] | (6.6%) | 8.9 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 82.0 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | (1,020.47) | [1,7-12] | (0.31) | 100.0 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 | |||||||
| Current ratio | 2.45x | [7-8] | 2.96x | 64.0 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 99.5 | |||||||
| Revenue growth, three-year compound | (88.0%) | [2,13-15] | 10.0% | 99.8 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| one or more required annual facts are missing | |||||||
| Asset growth, three years | (64.3%) | [1,6,16-17] | 2.1% | 99.1 | 704 | 2025-12-31 | |
| Net share issuance, one year | not computable | 2.5% | |||||
| prior share count is 30 days earlier | |||||||
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (29.5%) | 8.0% | 25 | hotter than 25 of 100 peers |
| Distance from 52-week high | (82.1%) | (31.4%) | 8 | closer to its high than 8 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | (149.5%) | (1.0%) | 4 | pricier than 96 of 100 peers |
| Book value to price | 0.33 | 0.28 | 55 | pricier than 45 of 100 peers |
| Sales to price | 0.00 | 0.31 | 4 | pricier than 96 of 100 peers |
| Composite equity issuance, five years | 57.4% | 20.3% | 67 | more equity-funded than 67 of 100 peers |
| Relative strength against the sector, log excess return | (0.56) | (0.14) | 25 | ahead of 25 of 100 peers |
Inputs: market equity $2.0M; EBIT -$4.2M; free cash flow -$3.0M; book equity $652,000; sales $5,000; cash $124,000[18].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (151.6%) | ✗ fail[4,6] |
| Operating cash flow above zero | -$2.9M | ✗ fail[5] |
| Return on assets improved | (95.0 pts) | ✗ fail[4,6,16,19] |
| Operating cash flow exceeds net income | $1.3M | ✓ pass[4-5] |
| Long-term leverage fell | n/a[1,6,16,20] | |
| Current ratio improved | (153.6 pts) | ✗ fail[7-8,21-22] |
| No new shares issued | n/a[23-24] | |
| Gross margin improved | n/a | |
| Asset turnover improved | 0.1 pts | ✓ pass[2,6,13,16] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $124,000[3] |
| Operating cash flow, four quarters | -$2.7M[3,5,25-28] |
| Months of runway | 0.5 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 56 |
| 10-Q received Aug 14, 2026 | |
| Median daily dollar volume | $22,476 |
| 63 sessions | |
| Days since newest grade input | 162 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $3.0M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $5,000 | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $124,000 | 2026-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
| 4 | net income | us-gaap:NetIncomeLoss | -$4.2M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.9M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 6 | assets | us-gaap:Assets | $2.8M | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 7 | current assets | us-gaap:AssetsCurrent | $2.0M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $813,000 | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$924.6M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$4.2M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 11 | book equity | us-gaap:StockholdersEquity | $2.2M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 12 | liabilities | us-gaap:Liabilities | $813,000 | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $10,000 | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $5,000 | 2023-12-31 | 2025-03-31 | 10-K | filing · viewer · series |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $2.9M | 2022-12-31 | 2024-04-01 | 10-K | filing · viewer · series |
| 16 | assets | us-gaap:Assets | $8.3M | 2023-12-31 | 2025-03-31 | 10-K | filing · viewer · series |
| 17 | assets | us-gaap:Assets | $64.9M | 2022-12-31 | 2024-04-01 | 10-K | filing · viewer · series |
| 18 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 2,540,480 | 2026-08-14 | 2026-08-14 | 10-Q | filing · viewer · series |
| 19 | net income | us-gaap:NetIncomeLoss | -$4.7M | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 20 | long term debt | us-gaap:LongTermDebtNoncurrent | $0 | 2024-12-31 | 2025-03-31 | 10-K | filing · viewer · series |
| 21 | current assets | us-gaap:AssetsCurrent | $2.8M | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 22 | current liabilities | us-gaap:LiabilitiesCurrent | $692,000 | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 23 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 2,402,372 | 2026-04-30 | 2026-04-30 | 10-K/A | filing · viewer · series |
| 24 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 2,378,253 | 2026-03-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.3M | 2026-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.0M | 2026-03-31 | 2026-05-15 | 10-Q | filing · viewer · series |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.3M | 2025-09-30 | 2025-11-14 | 10-Q | filing · viewer · series |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.5M | 2025-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.